Episode 8: Macro outlook, Microcap investing & Scorecard review

Are shares good value?

Is it time to take profits?

The last few decades have seen a sharp and prominent rise of software companies whose business models revolve around largely upfront development and marketing costs followed by ongoing recurring revenues. They have been dubbed as software as a service (SaaS) companies and there is no doubt that this has been a buzzword in recent times, justifiable or not. Often the […]

Shares in med-tech developer Polynovo (ASX:PNV) have doubled in the past year, driven by surging sales in its patented Novosorb product. More recently, the company revealed its first “million dollar month”, with sales for April ostensibly bringing the business to break-even on a monthly basis. What does the business do? Following a business restructure in 2014, Polynovo is focused on […]

Any investment that promises low risk and high returns is almost certainly a scam. It’s the financial equivalent of getting something for nothing — a fantasy that ends only in disappointment. In the real world, certainty comes at a price. And that price is lower returns. Think about it; if a largely ‘risk-free’ but high return investment were available, it would attract a […]

It wasn’t a great week for the market, with the All Ordinaries dropping a further 3% from its August all-time high. And there’s plenty of reasons to be nervous.  The US Federal Reserve is winding back stimulus and signalling higher lending costs. China — our largest trading partner — is facing a potential credit squeeze and property market slump, while trade […]

Time to buy or time to run?

Last week, I highlighted a curious reality: despite incredible advances in tech and productivity, most people are still working as much as ever just to cover the basics. Real wages have gone flat, while the costs of essentials like housing, healthcare, and energy keep climbing. Once you see it, it’s tough to ignore. It cries out for an explanation. It’s […]